Nanobiotix plans head and neck cancer treatment trial
Nanotech radiation therapy technology developer Nanobiotix said it will launch...Read more on AuntMinnie.com
CONCLUSION: Induction chemotherapy with Cisplatin and Docetaxel is a promising regimen with good response and favorable toxicity profile and can be considered as a potentially effective outpatient regimen for locally advanced squamous cell carcinoma of head and neck. PMID: 32212813 [PubMed - in process]
CONCLUSION: Once weekly low dose cisplatin treatment showed lower acute toxicity and a better compliance compared to once every 3 weeks high dose cisplatin treatment at the expense of a lower loco-regional control. PMID: 32212810 [PubMed - in process]
Publication date: Available online 19 March 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Nishant Vidyasagar, Janaki Manur Gururajachar
Publication date: Available online 18 March 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Zaheeda Mulla, Rolina K. Alwassia, Essam Mohammad Senan, Shamel Soaida, Ahmed Ahmed Mohamed Ameen Mohamed, Hussain Almerdhemah, Hafiz Asif Iqbal, Hane Mohammad Muamenah
Conclusion: Image-guided radiation therapy process detects the weight loss, which affects the treatment plan's dose distribution and should be corrected. Applying the correction method described here keeps the patient dosimetry within 1% of the original plan, which is clinically acceptable. The process of plan dosimetry correction to address weight loss can be completed within 30 min without repeating imaging and planning process.
Conclusions: At the time of writing of this study, there were more than 12,000 medical linear accelerators in clinical use, and XMLC can prove itself useful wherever linac is equipped with MLC but cannot delivery latest techniques, such as volumetric modulated arc therapy.
Chromosomal instability (CIN), an ongoing rate of chromosome missegregation events over the course of multiple cell divisions, is common in cancer. Low CIN can be weakly tumor promoting while high CIN causes rapid cell death due to loss of both copies of one or more essential chromosomes. Combining two independent insults that each cause low CIN results in high CIN, which leads to cell death and tumor suppression. Because radiation causes CIN, we hypothesize that pre-existing CIN, which has not been well characterized in head and neck cancer (HNC) and can be caused by human papilloma virus (HPV), sensitizes HNC cells to radiation therapy.
The incidence of thyroid cancer has been on the rise in recent decades with approximately 90% of these being differentiated thyroid carcinomas (DTCs) (including papillary and follicular). The majority of DTCs have a good prognosis and are potentially curable with standard treatment, the cornerstone of which is thyroidectomy. Commonly, patients may also receive adjuvant thyroid stimulating hormone suppression or radioactive iodine-131 (RAI). Due to a lack of randomized clinical trials, the role of adjuvant external beam radiation therapy (EBRT) in DTC is not well-established.
Proton beam radiation therapy has dosimetric advantages compared to photon radiation therapy for the treatment of major salivary gland tumors (MSGTs), due to the typically unilateral pattern of disease spread requiring only ipsilateral irradiation. However, clinical data on treatment outcomes and the potentially reduced toxicity with proton beam therapy is lacking.
Acute toxicities as a result of definitive radiation therapy (RT) +/- chemotherapy in head and neck cancer are severe and significant supportive care is needed for these patients. In order to complete the prescribed curative intent combined modality treatment, urgent care center (UCC) visits are common during treatment and may be needed even up to 8 weeks after the conclusion of all therapies resulting in substantial financial burden. Advanced Practice Practitioner (APP), whether a Nurse Practitioner or a Physician Assistant, who is integrated into the radiation oncology practice can be extremely valuable for these patients.